Podcasts about biomedical research

“We don't want to follow the crowd, we want to steer our own path into what we think are the most exciting opportunities for patients.” says Fiona Marshall, President of Biomedical Research at Novartis, joins Bloomberg Intelligence analyst Sam Fazeli to explain the biology-first, modality-second philosophy shaping R&D. Marshall details how Novartis is building radioligand therapy beyond Pluvicto into a broad portfolio across tumor types, while treating delivery as the bottleneck for expanding siRNA beyond the liver. The discussion also explores neuroscience as a growth bet built on earlier diagnosis and intervention, plus why AI productivity depends on embedding data scientists across the organization and training models on Novartis's proprietary data.See omnystudio.com/listener for privacy information.

狂賀！三腳貓要出第一個教授啦！恭喜雯薇要正式成為 PI, 開自己的 lab, 走出自己的路了！但如果是忠實聽眾一定會知道，雯薇常常會經歷很離奇驚險的遭遇，又常逢貴人相助、化險為夷，這段奇幻的找教職之旅，今天先從當初 PhD 畢業後找 postdoc 的抉擇，加入新實驗室後和老闆的磨合學習到的向上管理，蠟燭多頭燒的慢慢成為更獨當一面的科學家的旅程。 相關連結 EP060 - Peter, 雯薇常常諮詢 career 抉擇的厲害 PI EP017 - Angel 博班畢業的經歷，那時雯薇坐在紐約地鐵上感同身受的邊聽邊哭 工作人員 內容製作：雯薇、Angel 、若晴、天豪 後製：雯薇 文案：Angel 音樂：雯薇 封面：雯薇 上架：雯薇 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

In this episode of TGen Talks, we explore the art and responsibility of mentorship in biomedical research. Behind every breakthrough is not just data and experiments, but the guidance of seasoned scientists who shape the next generation. And while the results may not appear in a lab notebook, they're just as important. TGen neuroscientist and educator, Dr. John Fryer, joins the podcast to share how mentorship transforms careers, fosters resilience, and sparks creativity. From the lessons learned in his own training to the values he instills in his lab today, Dr. Fryer reminds us that science is an apprenticeship at heart, and choosing the right mentor can make all the difference in the world. Because in the end, the breakthroughs we celebrate are powered not only by experiments, but by the people who take the time to guide others along the way.

This episode of Healthy Dialogue explores the history and future of science funding in the US in light of recent changes, and proposed changes, from the federal government. Host Derek Angus, MD, MPH, speaks with former editor in chief of Science and a former director of the National Institute of General Medical Sciences at the NIH, Jeremy Berg, PhD. Related Content: Why and How Should the Government Fund Biomedical Research?

Lauren Stein, director of science and research programs at the National Anti-Vivisection Society, discusses emerging technologies that could transform biomedical research and reduce the need for animal testing.

After reading something that said her menstrual cycle changes her brain each month, Senior Correspondent Molly Webster goes on a reporting mission to see if that's true, and, if so, how. This journey into sex hormones and the brain involves females and males, and exacting self-experimentation. It gets into PTSD, and ends with a new twist on self-care (hint: it's biological). And, it starts to reveal a sneaky truth: that each one of us is at the mercy of a crashing sea of chemicals inside of us – those things we call hormones. Special thanks to Emily Jacobs, Laura Pritschet, Pavel Shapturenka, and Dr. Catherine Woolley.EPISODE CREDITS: Hosted by - Molly Webster Reported by - Molly Webster Produced by - Mona Madgavkar with help from - Molly Webster Fact-checking by - Diane A. Kelly EPISODE CITATIONS: Articles -  **The experiments we feature in this episode are called: 28andMe, 28andOC, and 28andHe, all of which took place at Emily Jacobs lab at the University of California, Santa Barbara.**  The 28 Project (https://zpr.io/CSx6MnwZjRvp), background from the Jacobs lab For more on how much variability there is between female and male animals, check out this “groundbreaking” study, referenced by Emily Jacobs in our episode Sex Bias in Neuroscience and Biomedical Research(https://zpr.io/ZRgKZzdNejUA),  by Beery AK, Zucker I., Neurosci Biobehav Rev. 2011 Dr. Catherine Woolley has revolutionized the field of neuroscience and sex hormones, here's more about her work … Sex Differences in the Brain Get Down to the Molecular Level Sex (https://zpr.io/UNCLE9J782N5), by Stephanie DeMarco, PhD, The Scientist.com Hormonal Effects on the Brain (https://zpr.io/DvNM9EkXdtGG), by Woolley, C.S. and Schwartzkroin, P.A. Epilepsia Data sets - 28andMe and 28andOC (https://zpr.io/hbXVNTVp2Q7j): 28andHe (https://zpr.io/sZXhfMbMwKb7) Audio -  In the episode, we mention Dr. Russ Poldrack and the Midnight Scan Club, as inspo for self-experimentation The Midnight Scan Club (https://zpr.io/CLBhNQSxK844), by Science Friday.   Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Jordan is rewriting the rules of healthcare. As the founder of Agency Health, he launched a cutting-edge Direct Primary Care practice built on a singular, uncompromising mission: to maximize your long-term independence, performance, and vitality. Jordan's medical philosophy is forged from an unconventional and powerful blend of disciplines. He began his career in Athletic Training, mastering the art of leveraging movement as medicine to optimize human performance. Driven by a deep curiosity for clinical science, he earned a Master's in Biomedical Research before completing his medical training at osteopathic medical school. This unique convergence—marrying high-level athletic rehabilitation, rigorous clinical research, and a holistic osteopathic approach—is the driving force behind Agency Health. Jordan doesn't just manage symptoms; he engineers personalized, preventive blueprints that empower you to own your health and live without limits.Find Dr. Leonard on IG/FB @theagencyhealth or at https://theagencyhealth.comWelcome to the Strength For Your Purpose Podcast where  Dr. Phil Finemore, PT, DPT, Cert. DN, Cert. VRS, owner of WorkFitME Mobile Physical Therapy, has a goal of helping busy Maine professionals find the mental, emotional, and physical strength to fulfill their true purpose in life. The mission is to approach the topic of wellness holistically and show you how outer and inner strength can spill over to all areas of life, creating waves of positive change in its path.It would mean so much to me if you took the time to subscribe, rate, and review the podcast. Please share with family, friends, and coworkers so they too can learn more about how to find their inner strength to fulfill their true purpose in life.Find Strength For Your Purpose Podcast on social media:Facebook: www.facebook.com/strengthforyourpurposepodIG: @strengthforyourpurposepodYouTube:    / @strengthforyourpurposepod  Find Dr. Phil and WorkFitME on social media:Facebook: www.facebook.com/phil.finemore and www.facebook.com/workfitmeIG: @drphil_fine_more and @workfitmeTwitter: @drphilptdpt and @workfitmeLinkedIn: www.linkedin.com/in/drphilptdpt and www.linkedin.com/company/workfitmeEmail: drphil@workfitme.com

David Brenner, President and CEO of Sanford Burnham Prebys Medical Discovery Institute, shares how collaboration, AI and biomedical innovation are transforming health outcomes and the regional economy. Brenner explains why San Diego's research ecosystem, philanthropy and public–private partnerships are critical to forward-thinking executives and civic leaders. Listen Where You Live!About Spotlight and Cloudcast Media  "Spotlight On The Community" is the longest running community podcast in the country, continuously hosted by Drew Schlosberg for 20 years.  "Spotlight" is part of Cloudcast Media's line-up of powerful local podcasts, telling the stories, highlighting the people, and celebrating the gravitational power of local.   For more information on Cloudcast and its shows and cities served, please visit www.cloudcastmedia.us. Cloudcast Media | the national leader in local podcasting.   About Mission Fed Credit Union  A community champion for over 60 years, Mission Fed Credit Union with over $6 billion in member assets, is the Sponsor of Spotlight On The Community, helping to curate connectivity, collaboration, and catalytic conversations.  For more information on the many services for San Diego residents, be sure to visit them at https://www.missionfed.com/

Hi everyone and thanks for joining me on this episode of Val Talk's Pets. In the news just recently has been the rescue of 1500 Beagles from Ridglan Farms, a biomedical research facility located in Blue Mound, Wisconsin, United States, that uses bred Beagles for experimentation. The size of this rescue was enormous, but unfortunately it was just the tip of the iceberg. And because of its significance, I thought we could go together and learn more about this incredible rescue. 

Send us Fan MailIs the US losing its edge in biomedical research—and what does that mean for the future of infectious diseases? In this episode, Jeanne Marrazzo, CEO of the Infectious Diseases Society of America and former leader at the National Institute of Allergy and Infectious Diseases, joins hosts Rebecca Alvania, PhD, MA, MPH, and Robert H. Hopkins, Jr., MD, for a timely, thought-provoking discussion on the future of public health and scientific research. From the early days of HIV to today's complex public health landscape, Marrazzo shares a candid look at the forces reshaping infectious diseases, including threats to scientific integrity, shifting research funding, vaccine confidence, and declining public trust. The conversation also explores what's at stake for US leadership in biomedical research, the impact on global health, and why patient advocacy and strong scientific voices are critical now. Follow NFID on social media

In this episode, we delve into the world of cutting-edge biomedical research with Dr. Jun Ding, an Assistant Professor in the Division of Respiratory Medicine at the McGill University Health Centre. Dr. Ding leads the Ding Lab at McGill University's Meakins-Christie Laboratories, where his research focuses on unraveling the complexities of cell dynamics in diseases through artificial intelligence and machine learning. Dr. Ding's work uses advanced single-cell technologies and computational biology to decode biological behaviors, leveraging machine learning models to transform massive omics datasets into meaningful biological insights. His innovative approach is driving breakthroughs in the understanding of complex diseases and offering new paths for diagnostics and therapeutics. In this conversation, we explore: ·       Why decoding cell dynamics is essential for understanding and treating complex diseases like cancer. ·       How single-cell and spatial omics technologies are revealing hidden layers of biological complexity. ·       The transformative role machine learning plays in predicting disease progression and identifying novel drug targets. If you're interested in the intersection of AI, biology, and healthcare, this episode is a must-listen for insights into the future of biomedical discovery. To learn more about Dr. Ding's research, visit The Ding Lab website! Episode also available on Apple Podcasts: https://apple.co/38oMlMr  Keep up with Dr. Ding socials here: X: https://x.com/johnding86 

EP065 靚蘋聊到美國後一路克服溝通障礙、打怪升級的研究故事，接下來要聊跌宕起伏的找教職過程啦！其中聊到在 NIH 當博後很難成為 PI 的迷思，歷經兩年半上 job market 的辛酸血淚，還有各種自我懷疑後最終來到最圓滿的現在結果。靚蘋又想建立一個怎麼樣的實驗室呢？歡迎有興趣的朋友找靚蘋聊聊喔！p.s. 最後有一個小彩蛋，相信三腳貓忠實聽眾們會會心一笑的！ 相關連結 新實驗室的網頁：https://jpinglin.github.io/ 工作人員 內容製作：靚蘋、Angel 後製：Angel、昶廷 文案：Angel 音樂：雯薇 封面：雯薇 上架：Angel 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

Epidemiologist Yvonne “Bonnie” Maldonado is an expert in vaccine research and public health. Look back centuries, and the story is always the same, she says: Death rates from viruses have plummeted, especially in children and the elderly. And yet, millions of children die each year from vaccine-preventable diseases. Vaccines need a return of public confidence, and that starts with better messaging and greater support of nongovernmental messengers like herself. The bottom line is that vaccines are safe, she says. Vaccines work and we have saved many lives because of them, Maldonado reminds host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Yvonne Maldonado Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Yvonne “Bonnie” Maldonado, a professor of pediatrics, epidemiology and population health at Stanford University. (00:03:01) Career in Vaccines Bonnie shares what led to her career in vaccine research. (00:04:53) How Vaccines Work How vaccines train the immune system to recognize and fight pathogens. (00:06:46) Why Vaccine Responses Vary The variability in immune responses and breakthrough infections. (00:09:22) Risk vs. Benefit in Vaccines How researchers evaluate side effects versus disease severity. (00:11:53) How Viruses Evolve The evolutionary dynamics that shape viral behavior. (00:13:59) Vaccine Boosters Why some vaccines last for life while others require multiple doses. (00:17:14) Herd Immunity How community protection works and why vaccination rates matter. (00:21:22) Vaccine Controversy The controversy surrounding vaccines and what led to it. (00:24:27) Global Vaccine Hesitancy How declining trust and past outbreaks influence vaccination globally. (00:27:07) The Future of Vaccines Why vaccines are essential and how outbreaks shape public response. (00:29:08) Preparing for Future Pandemics How healthcare systems prepare for new threats after COVID-19. (00:30:43) Future In a Minute Rapid-fire Q&A: hope, public trust, and the future of health. (00:32:54) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“Surround sound for biological cells,” is how Luke Cox describes the ultrasound technology that Impulsonics has developed to solve the “unsticking problem” in biomedical science. Cox is co-founder and chief executive of UK-based Impulsonics, which spun-out of the University of Bristol in 2023. He is also my guest in this episode of the Physics World Weekly podcast. He explains why living cells grown in a petri dish tend to stick together, and why this can be a barrier to scientific research and the development of new medical treatments. The system uses an array of ultrasound transducers to focus sound so that it frees-up and manipulates cells in a way that does not alter their biological properties. This is unlike chemical unsticking processes, which can change cells and impact research results. We also chat about Cox's career arc from PhD student to chief executive and explore opportunities for physicists in the biomedical industry. The following articles are mentioned in the podcast: “Materials probed by ultrasound…” podcast with Bruce Drinkwater “Portable imaging system targets eye diseases…” podcast with Siloton “Holographic acoustic tweezers could be used to create 3D displays” research done in Bruce Drinkwater’s lab

BUFFALO, NY — March 3, 2026 — A new #research perspective was #published in Volume 18 of Aging-US on February 24, 2026, titled “A decline in glycolytic ATP production is the fundamental mechanism limiting lifespan; species with an optimal rate of decline over time survived.” Led by Akihiko Taguchi — who is also the corresponding author and is affiliated with the Department of Regenerative Medicine Research, Foundation for Biomedical Research and Innovation at Kobe — the perspective advances a unifying conceptual framework in which a programmed or selected decline in glycolytic ATP production over the lifespan underlies aging phenotypes across species. The authors argue that glycolysis supplies the rapid ATP required for cell division and DNA/mitochondrial repair, and that a progressive reduction in glycolytic ATP with age can explain reduced cell proliferation, impaired repair, and other hallmark features of aging. “The simple explanation is that only species that happened to have an optimal rate of reduction in glycolytic ATP production over time were selected and survived through generational changes.” The perspective synthesizes evidence from comparative biology, cellular metabolism, and translational studies to link glycolytic decline with lifespan variation among species — for example, contrasting short-lived rodents with long-lived species such as the naked mole rat, which maintain high glycolytic flux in low-oxygen niches. The authors also highlight mechanisms connecting glycolysis to mitophagy, telomere dynamics, and proteostasis, arguing that maintaining glycolytic ATP supports repair processes while a shift toward oxidative metabolism improves energy efficiency under resource limitation but reduces rapid-repair capacity. The authors propose several concrete next steps to test the hypothesis. These include in vivo and in vitro interventions that modulate glycolysis (for example, gene transfer of glycolysis-related enzymes or pharmacologic activators such as terazosin), longitudinal measurements of glycolytic ATP production across aging cohorts, and comparative studies across species with differing lifespans to define the “optimal rate” of decline. They also suggest mechanistic studies of gap-junction–mediated metabolic coupling (for example, between hematopoietic stem cells and endothelium) and experiments to determine whether restoring glycolytic flux can rescue age-related deficits in DNA repair and tissue regeneration. While the perspective offers a coherent conceptual model, the authors are explicit about limitations and caution: the idea is currently a hypothesis that requires experimental validation, and the evolutionary rationale (selection for an optimal rate of glycolytic decline) must be tested by comparative and mechanistic work. Translation to human rejuvenation therapies — whether via stem-cell approaches, metabolic activators, or gene transfer — will require careful preclinical studies to evaluate efficacy, safety, and long-term consequences. DOI - https://doi.org/10.18632/aging.206356 Corresponding author - Akihiko Taguchi - taguchi@fbri.org Abstract video - https://www.youtube.com/watch?v=rA23radaoqI Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Angel 的好朋友靚蘋正式在美國拿到教職成為 PI 啦！靚蘋描述自己是個徹底的大Ｉ人，甚至有一點社恐，到美國後怎麼開始一級一級練功打怪，結交到超級 carry 的好朋友們，慢慢聽懂對話中背後的含義，訓練自己成為更好的科學家的歷程一步一步在這集剖析！科學又對靚蘋而言像是迷人的解謎遊戲，除了是個模式生物搜集狂，還不斷挑戰自己跨領域，拿到更多工具來幫助回答科學未竟之事。 相關連結 新實驗室的網頁：https://jpinglin.github.io/ 工作人員 內容製作：靚蘋、Angel 後製：Angel、昶廷 文案：Angel 音樂：雯薇 封面：雯薇 上架：Angel 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

Erin introduces a new cohost, Dave Bunnell who chats with his first guest, Jenn Aumiller about what she learned about mentorship, equity, and belonging in academic science through her research on mentoring experiences of Indian biomedical postdocs in the U.S.

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“The amount of chaos that's been introduced into the federal health policy landscape is unprecedented,” says Michelle Mello, professor at Stanford Law School and the Stanford University School of Medicine.That turmoil, she explains, has left major gaps in expertise, trust, and leadership—and states are rushing to fill the void. In this episode of Stanford Legal, host Pamela S. Karlan talks with Mello about what this moment means for the future of science, public health, research, and the law.Mello describes how the hollowing out of career expertise at the U.S. Department of Health and Human Services has upended vaccine policy and research funding, forcing states into unfamiliar leadership roles. She and Karlan also unpack how shifting scientific guidance during the pandemic eroded public confidence, how politicized grant-making is reshaping the research ecosystem, and state governments' growing role in creating what she calls a “shadow CDC.”Despite the turmoil, Mello points to a few bright spots: state-level experimentation could generate valuable evidence of what works and what does not, and there are reassuring signs from the lower courts, she says, which she believes are capable of separating law from politics.Earlier this year, Mello explored many of these themes in her JAMA Health Forum paper, “The Hard Road Ahead for State Public Health Departments.”Links:Michelle Mello >>> Stanford Law pageJAMA Health Forum paper >>> “The Hard Road Ahead for State Public Health DepartmentsConnect:Episode Transcripts >>> Stanford Legal Podcast WebsiteStanford Legal Podcast >>> LinkedIn PageRich Ford >>>  Twitter/XPam Karlan >>> Stanford Law School PageDiego Zambrano >>> Stanford Law School PageStanford Law School >>> Twitter/XStanford Lawyer Magazine >>> Twitter/X (00:00:00) Health Policy and COVID-19 Vaccines(00:05:10) The Vaccine Rollout Challenges(00:10:25) Public Trust and Recommendations(00:16:40) The Role of the Vaccine Committee(00:23:55) NIH Grant Process Insight(00:29:43) MIT's Stance on NIH Compact Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bioengineer Michael Fischbach studies alternative vaccine delivery methods, like self-administered creams with no needles, health professionals, or side effects. He teases a day when vaccines that don't make you feel bad come in the mail in ketchup-style packets. Such innovations would greatly improve vaccine uptake, especially in developing countries, and speed global response to novel viruses. It would change how we think about vaccines, Fischbach tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michael FischbachConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michael Fischbach, a professor of bioengineering at Stanford University.(00:04:24) Cream-Based VaccinesThe discovery that revealed the skin's ability to spark systemic immunity.(00:07:36) Engineering ImmunityModifying staph epidermidis to carry antigens and test immune response.(00:09:38) Tumor RegressionHow engineered bacteria triggered tumor-killing immunity in mice.(00:12:53) Antibody DiscoveryEvidence that skin exposure can generate long-lasting antibodies.(00:17:02) Antibody Response in HumansWhether humans show antibody responses to their own skin bacteria.(00:18:42) Turning Bacteria into VaccinesEmbedding harmless pathogen fragments into bacterial surface proteins.(00:20:55) Immunity Without ShotsHow mice achieved vaccine-level immunity through topical application.(00:24:00) Reimagining Vaccine DeliveryThe potential for self-applied, needle-free, and multiplexed vaccines.(00:26:50) Mechanism Behind Skin ImmunityHow skin immune cells may constantly sample microbes for defence.(00:28:14) Next Steps in DevelopmentThe path toward testing safety, dosage, and delivery in higher models.(00:29:57) Choosing Vaccine TargetsViruses and diseases that could be targets for early skin-based vaccines.(00:31:11) Safety and ReversibilityEnsuring safety with reversible bacteria and limited trial participants.(00:33:04) Transitioning to BiotechTransitioning research from Stanford to large-scale biotech development.(00:34:31) Future In a MinuteRapidfire Q&A: creative science, vaccine innovation, and biology's future.(00:36:56) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Robert Wicks, Vice President of Philanthropy at Gladstone Institutes and the CEO of the Gladstone Foundation, talks about the impact of philanthropy as a social good; the endless possibilities of medicine today with the biomedical revolution and artificial intelligence; and the Gladstone Now Campaign.About Spotlight and Cloudcast Media  "Spotlight On The Community" is the longest running community podcast in the country, continuously hosted by Drew Schlosberg for 19 years.  "Spotlight" is part of Cloudcast Media's line-up of powerful local podcasts, telling the stories, highlighting the people, and celebrating the gravitational power of local.   For more information on Cloudcast and its shows and cities served, please visit www.cloudcastmedia.us. Cloudcast Media | the national leader in local podcasting.   About Mission Fed Credit Union  A community champion for over 60 years, Mission Fed Credit Union with over $6 billion in member assets, is the Sponsor of Spotlight On The Community, helping to curate connectivity, collaboration, and catalytic conversations.  For more information on the many services for San Diego residents, be sure to visit them at https://www.missionfed.com/

Dr. Daniel Linzer retired as President Emeritus of the Research Corporation for Science Advancement in July of this year after eight years of leadership. He joined RCSA from Northwestern University where he was on the faculty as professor of molecular biosciences and served as Provost for a decade following stints as dean and associate dean of arts and sciences. Dr. Linzer earned his doctorate from Princeton and his undergraduate degree from Yale and was a post-doctoral fellow at the Johns Hopkins University School of Medicine. During his career, his research and teaching were recognized and awarded by the Searle Scholars Award, the American Cancer Society Faculty Research Award, and the Northwestern Alumni Association Excellence in Teaching Award. His research on the P53/TP 53 gene was groundbreaking since it is a tumor suppression gene and therefore is fundamental to understanding cancer and a person's predisposition to cancer. His work led to discoveries identifying hormones that influence cellular development.

Peter Maurer, Assistant Professor of Molecular Engineering at the University of Chicago Pritzker School of Molecular Engineering, speaks with Pitt's HexAI podcast host, JordanGass-Pooré, about the future impact of quantum sensing on biomedical research and diagnostics.Peter's research lab leverages the extreme environmental sensitivity of quantum systems to develop powerful sensors suitable for cutting-edge biological research that are optically addressable and can operate under ambient conditions. He outlines both near-term and future applications of powerful quantum sensors in pathology and laboratory medicine. He provides a key example of how these sensors could enable a new type of nanoscale NMR spectroscopy, capable of measuring magnetic fields from biomolecules to non-invasively probe their chemical information and signaling pathways. In the near future, he points to diagnostic tools, currently being developed by companies, that use the unique optical signatures of quantum sensors for highly sensitive, background-free protein detection in small volumes. For the long term, he envisions the technology as a "field opener" for studying protein aggregation in neurodegenerative diseases like Alzheimer's and Parkinson's.Peter outlines how AI can be applied to analyze complex data from sensors that respond to multiple environmental factors and highlights the challenge of bringing together experts from quantum technology, biophysics, and medicine who can "talk each other's language.” He also touches on how the use of synthetic data in quantum sensing is a "completely under-appreciated" area with the potential to analyze complex environmental properties that would otherwise be missed by looking at single types of measurements. To advance the field from academic proofs-of-concept to clinical tools, he stresses the need for collaboration with academic and industry partners who can help engineer robust, "turnkey" systems that can be widely tested and used.The University of Pittsburgh Health and Explainable AI podcast is a collaborative initiative between the Health and Explainable AI (HexAI) Research Laboratory in the Department of Health Information Management at the School of Health and Rehabilitation Sciences, and the Computational Pathology and AI Center of Excellence (CPACE), at the University of Pittsburgh School of Medicine.Hosted by Jordan Gass-Pooré, a health and science reporter, this podcast series explores the transformative integration of responsible and explainable artificial intelligence into health informatics, clinical decision-making, and computational medicine. From reshaping diagnostic accuracy to enhancing patient care pathways, we'll highlight how AI is creating new bridges between researchers, clinicians, and healthcare innovators. Led by Ahmad P. Tafti, Hooman Rashidi and Liron Pantanowitz, the HexAI podcast is committed to democratizing knowledge around ethical, explainable, and clinically relevant AI. Through insightful conversations with domain experts, AI practitioners and students will spotlight the latest breakthroughs, discuss real-world applications, and unpack the challenges and opportunities that lie ahead in responsible AI in healthcare. So whether you're a student, practitioner, researcher, or policymaker, this is your gateway to the future of AI-powered healthcare

Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential figure behind such research institutions as the Whitehead Institute for Biomedical Research and the Broad Institute. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the legacy of Baltimore, who passed away this past weekend at 87.The analysts also discuss Atlas Venture's new $400 million opportunity fund, the clinical development pipelines for metabolic-associated steatohepatitis (MASH) and chronic urticaria, and late-stage atopic dermatitis data from Sanofi. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656942#biotech #biopharma #DavidBaltimore #ReverseTranscriptase #MASH #Rezdiffra #GLP1 #ChronicUrticaria #Dupixent00:01 - Sponsor Message: IQVIA Biotech03:19 - Remembering David Baltimore06:20 - Atlas' New Opportunity Fund09:16 - The Growing MASH Pipeline15:57 - Sanofi's Atopic Dermatitis Data18:51 - Exploring Chronic Urticaria TreatmentsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

For the series finale, Peter Lee, Carey Goldberg, and Dr. Zak Kohane compare their predictions to insights from the series' most recent guests, including experts on AI's economic and societal impact, leaders in AI-driven medicine, and doctors in training.Show notes

Aubrey Masango speaks to Dr Pritika Ramharack Specialist scientist at the Biomedical Research and Innovation Platform in the South African Medical Research Council looking into the groundbreaking medical and science training centre that has been launched in Pretoria, The Centre for Advanced Training and Innovative Research . They touch on it's mission to bridge the gap in scientific skills across South Africa and give students from underprivileged backgrounds hands-on experience in laboratory work.Tags: 702, The Aubrey Masango Show, Aubrey Masango, Education Feature, Dr Pritika Ramharack, Technology, Innovation, Research, Pretoria, Laboratory workThe Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

High Performance Computing is here for the masses!Enterprises are bleeding budget in the public cloud, shackled to legacy on-prem systems, and wrestling with HPC workflows so complex they require armies of admins just to keep them running. In this episode, I talk to Matthew Shaxted, Founder & CEO of Parallel Works, about how their ACTIVATE platform is breaking that lock-in, unifying HPC, AI, and hybrid cloud computing into one seamless control plane.Think democratized supercomputing — where scientists, researchers, engineers, and AI teams get instant, intuitive access to powerful compute resources without becoming system admins. ACTIVATE abstracts away the messy plumbing of schedulers, chipsets, and hybrid environments, enabling workloads to run seamlessly across on-prem, multi-cloud, and GPU clusters. From high-security IL5/CUI/ITAR deployments to real-time cost control and AI-driven physics model replacement, Parallel Works is lowering the complexity barrier and unlocking HPC for the AI era.Parallel Works was founded in 2014 in Chicago, IllinoisTechnology & Topics Mentioned:HPC, AI Orchestration, Hybrid Cloud, OpenStack, Kubernetes, GPU Clusters, Multi-GPU Nodes, IL5 Security, CUI/ITAR Compliance, Workflow Automation, Cost Governance, Scientific Computing, Predictive Modelling, Scheduler Abstraction, HPCwire Top Cloud Platform, Cloud Repatriation, NOAA, Biomedical Research, Space Weather Modelling, ML-based Physics ReplacementGreat Things with Great Tech Podcast: https://gtwgt.comGTwGT Playlist on YouTube: https://www.youtube.com/@GTwGTPodcastListen on Spotify: https://open.spotify.com/show/5Y1Fgl4DgGpFd5Z4dHulVXListen on Apple Podcasts: https://podcasts.apple.com/us/podcast/great-things-with-great-tech-podcast/id1519439787EPISODE LINKSParallel Works Website: https://www.parallelworks.comParallel Works on LinkedIn: https://www.linkedin.com/company/parallel-worksMatthew Shaxted on LinkedIn: https://www.linkedin.com/in/matthewshaxtedGTwGT LINKSSupport the Channel: https://ko-fi.com/gtwgtBe on #GTwGT: Contact via Twitter/X @GTwGTPodcast or visit https://www.gtwgt.comSubscribe to YouTube: https://www.youtube.com/@GTwGTPodcast?sub_confirmation=1Great Things with Great Tech Podcast Website: https://gtwgt.comSOCIAL LINKSFollow GTwGT on Social Media:Twitter/X: https://twitter.com/GTwGTPodcastInstagram: https://www.instagram.com/GTwGTPodcastTikTok: https://www.tiktok.com/@GTwGTPodcast

அமெரிக்க விண்வெளி ஆராய்ச்சி நிறுவனமான நாசாவில், உயிர் மருத்துவவியல் ஆராய்ச்சி மற்றும் சுற்றுச்சூழல் அறிவியல் (Biomedical Research and Environmental Sciences) பிரிவின் துணைத் தலைவராகப் பணியாற்றும் டாக்டர் அந்தோனி ஜீவராஜன் அவர்கள் செவ்வாய்க்கு மனிதனை அனுப்பும் திட்டத்திலும் தனது பணியை செய்து வருகிறார். தனது பணி குறித்தும் நாசா குறித்தும் குலசேகரம் சஞ்சயனுடன் 2016ஆம் ஆண்டில் Dr. Antony Jeevarajan உரையாடியிருந்தார். அந்த நேர்காணலின் மறு ஒலிபரப்பு இது.

Dr. Hoffman continues his conversation with Dr. Chris Rhodes, a clinical fasting, longevity, and biomimetics researcher at UC Davis.

Dr. Chris Rhodes, a clinical fasting, longevity, and biomimetics researcher at UC Davis, discusses various fasting methods including time-restricted feeding, intermittent fasting, and prolonged fasting. He highlights the biochemical processes involved, such as autophagy and metabolic adaptation, and underscores the potential health benefits of fasting, which include improved metabolic markers and extended lifespan as evidenced in animal models. Dr. Rhodes also introduces Mimio, a supplement developed from his research designed to mimic the benefits of fasting without actual food deprivation, detailing its composition and the promising clinical results. The discussion weaves through scientific insights, personal experiences, and practical applications of fasting and fasting-mimicking agents.

- 导语 -长期以来，药物研发的公平性议题备受社会关注。丁胜博士在制药领域深耕多年，从研究干细胞领域拓展至创建多家生物技术公司。2015年，丁胜选择回国筹建清华药学院，次年创办全球健康药物研发中心（GHDDI），通过这一公益性的新药研发中心，支持全球健康和发展目标的实现。为什么疟疾、结核病等传染病是“被忽视的疾病”？青蒿素问世后，抗疟药物为何仍需经历多次迭代升级？人工智能技术如何辅助药物研发？面对抗癌天价药，如何在创新激励与药品可及性之间寻求平衡？请听本期嘉宾丁胜带来的精彩分享。- 本期话题成员 -程衍樑（微博@GrenadierGuard2）丁胜，全球健康药物研发中心主任，清华大学药学院首任院长、拜耳特聘教授。- 时间轴 -01:17 丁胜师从加州生物医学研究所创始人彼得·舒尔茨03:31 美国医药研究与大型药物研发公司的人才流通05:11 作为共同创始人，参与创建多家生物技术公司09:47 百万一针、非「现货型」：CAR-T疗法治疗癌症的局限性16:36 从创业者到院长：回国筹建清华药学院及创办GHDDI21:21 清华药学院专注上游科研，GHDDI攻坚下游药物创新23:22 专攻「穷病」：疟疾与结核的药物研发为何被忽视29:03 青蒿素之后，抗疟药为何仍需升级？33:23 「创新药物的平均成功率不到10%」34:21 新冠让抗病毒药物研发成为新重点36:07 从大模型到智能体，AI怎么帮助研发新药？39:39 ChatGPT创始人Sam Altman投资丁胜参与创办的抗衰公司46:21 天价药困境：创新与公平的定价平衡难题- 本期术语 -GHDDI（Global Health Drug Discovery Institute）全球健康药物研发中心于2016年在北京成立，是由清华大学、北京市政府和盖茨基金会联合创办的一所独立运营、非营利性质的创新药物研发机构。CAR-T疗法（Chimeric Antigen receptor T cells）嵌合抗原受体T细胞免疫疗法，近年来兴起的一种治疗肿瘤的精准靶向疗法。TSRI（The Scripps Research Institute）斯克利普斯研究所，一所私立的非营利性的生物医学研究机构。Calibr（California Institute for Biomedical Research）加州生物医学研究所，一家独立的非营利机构，成立于 2012 年，旨在加速基础研究向新药的转化，以解决尚未满足的医疗需求。NiV（尼帕病毒）亨尼巴病毒属的一种RNA病毒，通常在特定种类的果蝠之间传播。- 制作团队 -声音设计 hotair节目统筹 禾放节目运营 小米粒节目制作 hualun 思钊 Yologo设计 杨文骥- 音乐 -Danse Macabre - Busy Strings - Kevin MacLeod- 本节目由JustPod出品 © 2025 上海斛律网络科技有限公司 -- 互动方式 -商务合作：ad@justpod.fm微博：@忽左忽右leftright @播客一下 @JustPod微信公众号：忽左忽右Leftright / JustPod / 播客一下小红书：JustPod气氛组 / 忽左忽右B站：忽左忽右leftright抖音：忽左忽右

- 导语 - 长期以来，药物研发的公平性议题备受社会关注。丁胜博士在制药领域深耕多年，从研究干细胞领域拓展至创建多家生物技术公司。2015年，丁胜选择回国筹建清华药学院，次年创办全球健康药物研发中心（GHDDI），通过这一公益性的新药研发中心，支持全球健康和发展目标的实现。为什么疟疾、结核病等传染病是“被忽视的疾病”？青蒿素问世后，抗疟药物为何仍需经历多次迭代升级？人工智能技术如何辅助药物研发？面对抗癌天价药，如何在创新激励与药品可及性之间寻求平衡？请听本期嘉宾丁胜带来的精彩分享。 - 本期话题成员 - 程衍樑（微博@GrenadierGuard2） 丁胜，全球健康药物研发中心主任，清华大学药学院首任院长、拜耳特聘教授。 - 时间轴 - 01:17 丁胜师从加州生物医学研究所创始人彼得·舒尔茨 03:31 美国医药研究与大型药物研发公司的人才流通 05:11 作为共同创始人，参与创建多家生物技术公司 09:47 百万一针、非「现货型」：CAR-T疗法治疗癌症的局限性 16:36 从创业者到院长：回国筹建清华药学院及创办GHDDI 21:21 清华药学院专注上游科研，GHDDI攻坚下游药物创新 23:22 专攻「穷病」：疟疾与结核的药物研发为何被忽视 29:03 青蒿素之后，抗疟药为何仍需升级？ 33:23 「创新药物的平均成功率不到10%」 34:21 新冠让抗病毒药物研发成为新重点 36:07 从大模型到智能体，AI怎么帮助研发新药？ 39:39 ChatGPT创始人Sam Altman投资丁胜参与创办的抗衰公司 46:21 天价药困境：创新与公平的定价平衡难题 - 本期术语 - GHDDI（Global Health Drug Discovery Institute） 全球健康药物研发中心于2016年在北京成立，是由清华大学、北京市政府和盖茨基金会联合创办的一所独立运营、非营利性质的创新药物研发机构。 CAR-T疗法（Chimeric Antigen receptor T cells） 嵌合抗原受体T细胞免疫疗法，近年来兴起的一种治疗肿瘤的精准靶向疗法。 TSRI（The Scripps Research Institute） 斯克利普斯研究所，一所私立的非营利性的生物医学研究机构。 Calibr（California Institute for Biomedical Research） 加州生物医学研究所，一家独立的非营利机构，成立于 2012 年，旨在加速基础研究向新药的转化，以解决尚未满足的医疗需求。 NiV（尼帕病毒） 亨尼巴病毒属的一种RNA病毒，通常在特定种类的果蝠之间传播。 - 制作团队 - 声音设计 hotair 节目统筹 禾放 节目运营 小米粒 节目制作 hualun 思钊 Yo logo设计 杨文骥 - 音乐 - Danse Macabre - Busy Strings - Kevin MacLeod - 本节目由JustPod出品 © 2025 上海斛律网络科技有限公司 - - 互动方式 - 商务合作：ad@justpod.fm 微博：@忽左忽右leftright @播客一下 @JustPod 微信公众号：忽左忽右Leftright / JustPod / 播客一下 小红书：JustPod气氛组 / 忽左忽右 B站：忽左忽右leftright 抖音：忽左忽右

- 导语 -长期以来，药物研发的公平性议题备受社会关注。丁胜博士在制药领域深耕多年，从研究干细胞领域拓展至创建多家生物技术公司。2015年，丁胜选择回国筹建清华药学院，次年创办全球健康药物研发中心（GHDDI），通过这一公益性的新药研发中心，支持全球健康和发展目标的实现。为什么疟疾、结核病等传染病是“被忽视的疾病”？青蒿素问世后，抗疟药物为何仍需经历多次迭代升级？人工智能技术如何辅助药物研发？面对抗癌天价药，如何在创新激励与药品可及性之间寻求平衡？请听本期嘉宾丁胜带来的精彩分享。- 本期话题成员 -程衍樑（微博@GrenadierGuard2）丁胜，全球健康药物研发中心主任，清华大学药学院首任院长、拜耳特聘教授。- 时间轴 -01:17 丁胜师从加州生物医学研究所创始人彼得·舒尔茨03:31 美国医药研究与大型药物研发公司的人才流通05:11 作为共同创始人，参与创建多家生物技术公司09:47 百万一针、非「现货型」：CAR-T疗法治疗癌症的局限性16:36 从创业者到院长：回国筹建清华药学院及创办GHDDI21:21 清华药学院专注上游科研，GHDDI攻坚下游药物创新23:22 专攻「穷病」：疟疾与结核的药物研发为何被忽视29:03 青蒿素之后，抗疟药为何仍需升级？33:23 「创新药物的平均成功率不到10%」34:21 新冠让抗病毒药物研发成为新重点36:07 从大模型到智能体，AI怎么帮助研发新药？39:39 ChatGPT创始人Sam Altman投资丁胜参与创办的抗衰公司46:21 天价药困境：创新与公平的定价平衡难题- 本期术语 -GHDDI（Global Health Drug Discovery Institute）全球健康药物研发中心于2016年在北京成立，是由清华大学、北京市政府和盖茨基金会联合创办的一所独立运营、非营利性质的创新药物研发机构。CAR-T疗法（Chimeric Antigen receptor T cells）嵌合抗原受体T细胞免疫疗法，近年来兴起的一种治疗肿瘤的精准靶向疗法。TSRI（The Scripps Research Institute）斯克利普斯研究所，一所私立的非营利性的生物医学研究机构。Calibr（California Institute for Biomedical Research）加州生物医学研究所，一家独立的非营利机构，成立于 2012 年，旨在加速基础研究向新药的转化，以解决尚未满足的医疗需求。NiV（尼帕病毒）亨尼巴病毒属的一种RNA病毒，通常在特定种类的果蝠之间传播。- 制作团队 -声音设计 hotair节目统筹 禾放节目运营 小米粒节目制作 hualun 思钊 Yologo设计 杨文骥- 音乐 -Danse Macabre - Busy Strings - Kevin MacLeod- 本节目由JustPod出品 © 2025 上海斛律网络科技有限公司 -- 互动方式 -商务合作：ad@justpod.fm微博：@忽左忽右leftright @播客一下 @JustPod微信公众号：忽左忽右Leftright / JustPod / 播客一下小红书：JustPod气氛组 / 忽左忽右B站：忽左忽右leftright抖音：忽左忽右

Daphne Koller, Noubar Afeyan, and Dr. Eric Topol, leaders in AI-driven medicine, discuss how AI is changing biomedical research and discovery, from accelerating drug target identification and biotech R&D to helping pursue the “holy grail” of a virtual cell.Show notes

In a conversation recorded at the WBUR Festival, Dr. Anthony Fauci speaks frankly about the threats he sees to public health under the Trump administration and the “severe intimidation” of scientists at the NIH.

Na série de conversas descontraídas com cientistas, chegou a vez da Bióloga, Mestra e Doutora em Farmacologia/Psicofarmacologia, e Livre-Docência em Psicobiologia, Malu Formigoni.Só vem!>> OUÇA (119min 37s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*Maria Lucia Oliveira de Souza Formigoni é graduada em Ciências Biológicas Modalidade Médica pela Escola Paulista de Medicina, onde concluiu o Mestrado, Doutorado em Farmacologia/Psicofarmacologia e Livre-Docência em Psicobiologia.É professora titular do Departamento de Psicobiologia da EPM-UNIFESP e presidente do Instituto de Estudos Avançados e Convergentes da UNIFESP. Entre 1997 e 2007 foi coordenadora do Programa de Pós-Graduação em Psicobiologia (nota 7 da CAPES), tendo sido também chefe do Departamento de Psicobiologia da EPM.Foi duas vezes Pró-reitora de Pós-Graduação e Pesquisa da Universidade Federal de São Paulo.Chefiou a Disciplina de Medicina e Sociologia do Abuso de Drogas do Departamento de Psicobiologia da UNIFESP.Atua em diversas sociedades científicas/comitês de experts: foi editora-assistente da revista Addiction, é membro do corpo editorial das revistas Addiction Science Clinical Practice e Journal of Mental Health and Addiction, Editora Associada da Frontiers in Digital Health, parecerista de vários periódicos nacionais e internacionais.É membro da Research Society on Alcoholism (RSA), da Latin American Society for Biomedical Research on Alcoholism (LASBRA), foi vice-presidente da ISBRA (International Society of Biomedical Research on Alcoholism - 2006-2010).Foi co-presidente da INEBRIA (International Network on Brief Interventions for Alcohol and other drugs, atualmente membro do seu Coordination Committe.Foi membro temporário do comitê de experts da Organização Mundial de Saúde (OMS) para definição das Políticas sobre Álcool e consultora da SENAD (Secretaria Nacional de Políticas sobre Drogas).Preside o conselho fiscal da Associação Fundo de Incentivo à Pesquisa (AFIP).Coordena pesquisas básicas em Neurobiologia do Abuso de Drogas e projetos clínicos/epidemiológicos sobre alcoolismo e dependência de drogas, principalmente sobre detecção precoce do uso e intervenções breves presenciais e digitais e sobre efeitos de bebidas energéticas. Foi coordenadora no Brasil de projetos multicêntricos internacionais desenvolvidos por pesquisadores apoiados pelo Substance Abuse Department of WHO (World Health Organization).Desenvolveu a versão brasileira da intervenção virtual www.bebermenos.org.br. Em parceria com a Secretaria Nacional de Políticas sobre Drogas, idealizou e coordenou os cursos de capacitação por Educação à Distância SUPERA (Sistema para detecção do Uso abusivo e dependência de substâncias Psicoativas: Encaminhamento, intervenção breve, Reinserção social e Acompanhamento), ofertado a 145.000 profissionais de saúde de todos os estados do país e o curso Fé na Prevenção, ofertado a 25.000 líderes religiosos e comunitários.Lattes: http://lattes.cnpq.br/6528718059938788*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

The National Institutes of Health have a new Director…one with vision, defined goals, and a bold reform agenda. Meet our nation's new top biomedical scientist and discover his ‘Blueprint for the Future of Biomedical Research," inside this edition of CTSI Discovery Radio!

睽違半年Happy Hour總算更新啦！這次若晴跟Angel來聊聊最近剛從研討會回來的一些見聞和心得，非常適合搭配上一集新手村005一起收聽！當然我們也不忘Happy Hour的慣例，跟大家分享了一則近期非常振奮人心的客製化基因療法突破的新聞。等待Happy Hour已久的聽眾趕緊收聽吧！ 節目內容： 跟大家更新一下近況 客製化基因療法大突破 芝加哥三腳貓4/6小聚 AACR開幕式小花絮 跟同事學了poster session的搜集資訊的招數 小廢物拿好拿滿還有免費專業大頭照 NIH fellowship小會議見聞 會議結識新朋友的喜悅 -- Hosting provided by SoundOn

To discuss a novel treatment for Mosquitoes with Malaria, John Maytham is joined by Dr Dale Taylor | Malaria Researcher at the H3D Centre, University of Cape Town. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

BrainStorm wants to hear from you! Send us a text.in this episode of the "BrainStorm" by UsAgainstAlzheimer's, George Vradenburg, Co-founder and Chairman of UsAgainstAlzheimer's, and Russ Paulsen, the organization's Chief Operating Officer, discuss the impact of the Trump administration's policies on Alzheimer's research with host Meryl Comer. The conversation highlights the systematic dismantling of the National Institutes of Health (NIH) and other critical agencies, which threatens to undermine Alzheimer's research and public health. Vradenburg and Paulsen express concerns about the lack of transparency in the reorganization and the potential negative effects on drug reviews and approvals due to significant cuts at the FDA. They highlight the importance of protecting key programs that support seniors and the potential global impact of these policy changes. Despite the challenges, both Paulsen and Vradenburg are optimism about scientific advances in diagnosing and treating Alzheimer's, including the development of blood tests and new treatments. Hear the call to action for listeners to advocate for continued support for Alzheimer's research and to contact their members of Congress to ensure that funding remains a priority. This is a must listen episode!  This episode is sponsored by Genentech.Support the show

We want to hear from you! Send us a text.Journalist and author Greg O'Brien, diagnosed with early-onset Alzheimer's over a decade ago, shares with BrainStorm host Meryl his determination to be heard at the Washington D.C. rally at the Lincoln Memorial to protest proposed cuts to NIH biomedical research funding that would critically affect Alzheimer's disease research.  Greg also candidly shares what it takes for him to navigate at this late stage in the disease.This episode also features a TopLine commentary by George Vradenburg, founder and chair of UsAgainstAlzheimer's, on the mobilization of patient advocacy organizations across diseases fighting to maintain the integrity of America's biomedical and scientific research.This episode is sponsored by Genentech.Support the show

這集三腳貓新手村一起來聊聊大家開始怎麼漸漸習慣美國生活的呢？大家都是如何把美國當作自己的第二個家呢？來聽聽天豪、若晴及雯薇的經驗吧！ 大城市 vs 小城市 民以食為天！ 極度縮水的spinach 西方超市 vs 亞洲超市 Meal prep是讓人可以開始在家裡做東西的動力之一 一不小心吃的就講了一個小時 該如何為不同的美國氣候準備衣服呢？ Outlet及連假特價是購入衣服的好時機 圖書館有很多好用的資源！ 運動的資源很多，記得要多運動維持自己的身體健康 學會醫療保險及Student health的運作及使用方式 生小孩的帳單是多少？想知道更多的請留言！ 善用信用卡點數的點數玩家們 可以先從cash back開始累積信用 其實仔細找找也有學生票或是免費的藝文活動 大家當初想要給自己的一句話：請早點開始用退休金帳戶Roth IRA!!!! 貓與小孩 冥想 結尾：生活也是能讓自己長久追求夢想的重要因子之一 工作人員 內容製作：雯薇、若晴、天豪 後製：雯薇 文案：雯薇 音樂：雯薇 封面：雯薇 上架：雯薇 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

A panel discussion of a Presidential Advisory from the American Heart Association that outlines the importance of funding for scientific research and the need for a robust National Institutes of Health. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington INCLUDE URLS and full titles for some of the pertinent studies cited. You may also like: Principles for the Future of Biomedical Research in the United States and Optimizing the National Institutes of Health: A Presidential Advisory From the American Heart Association https://doi.org/10.1161/cir.0000000000001319 The Role of Public-Sector Research in the Discovery of Drugs and Vaccines." https://www.nejm.org/doi/full/10.1056/NEJMsa1008268 Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 https://pubmed.ncbi.nlm.nih.gov/37115539/ Hear John Mandrola, MD's summary and perspective on the top cardiology news each week on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Synopsis: Building in biotech isn't for the faint of heart—especially during a market downturn. But that's exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech's toughest cycles—and emerged stronger each time. Hosted by Rahul Chaturvedi, this conversation dives into what it really takes to launch and scale biotech companies: from mastering the evolution of the CEO role to raising nearly $900M through strategic partnerships, to knowing when it's time to pass the torch. Steve also shares how Mission BioCapital is rewriting the playbook for early-stage innovation through its Platinum Program, offering $500K and lab access to science founders ready to launch bold new ideas. Real talk, real strategies, and a blueprint for building lasting biotech companies—especially when its hardest. Biography: Steve Tregay, PhD is a Managing General Partner based in our Cambridge office. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and Nocion Therapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares. Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma. Steve received his doctoral and Master's degrees in organic chemistry from Harvard University and a Bachelor's from Davidson College.

Former NIH director Dr. Harold Varmus speaks out about what recent budget cuts and policy changes could mean for science.One of the areas targeted by President Trump's administration for cuts has been the National Institutes of Health (NIH). Cost-cutting actions have included the layoffs of some 1,200 NIH employees, the termination of research grants, a pause in the “study sections” that evaluate and award grant funding, and a cap on indirect costs included in research grants. Some of those moves have been paused following court cases. Dr. Harold Varmus, a former director of the National Institutes of Health, joins Host Ira Flatow to talk about the actions, and the impact he fears they could have on the future of biomedical research in the United States.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Reproductive health is historically understudied and underfunded in the United States. Scientists across Connecticut and beyond have been working to change that. Scientific initiatives like EndoRISE, a Connecticut-based program focused on advancing endometriosis research, are making strides toward better understanding reproductive health. This hour, we explore how President Trump’s recent funding cuts could impact their progress. GUESTS: Michayla Savitt: State Government Reporter, CT Public Dr. Danielle Luciano: Associate Professor of Obstetrics and Gynecology and co-director of EndoRISE Dr. Lubna Pal: Professor of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine Julie Rovner: Chief Washington Correspondent, KFF Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.

原本會成為一名，要用簡單易懂的語言，引導小學生快樂成長的國小老師。Melinda在一次無心插柳下的「大學人生小探險」，居然走著繞著，就這樣走上了生醫研究的道路，也在這條路上遇到幾位風格各異的學術導師，帶著她逐漸穩步向前，從台灣的插花生醫實驗室小工，一路走到現在，成為OMRF的博士後研究人員。繼上次來介紹奧克拉荷馬之後，讓我們再來聽聽Melinda分享，她這相較之下，不那麼典型的生醫職涯起步歷程，以及她從幾位指導教授身上，學習到什麼各式獨門神技，並且對她的人生思考及未來規劃有些什麼影響。 喔對了！想知道Melinda有沒有在今年的state fair吃到炸小熊軟糖嗎?這集也會公佈結果喔！ *本集勘誤：Dr. Rod McEver發現的是P-selectin，不是PECAM1 延伸閱讀 何彥君實驗室網頁 https://www.ibms.sinica.edu.tw/yen-chun-ho/ch/ Melinda博後實驗室主持人Courtney Griffin的TED演講** **https://www.youtube.com/watch?v=JTBg6hqeuTg 工作人員 內容製作：Melinda、Angel、天豪 後製：天豪 文案：天豪 音樂：雯薇 封面：雯薇 上架：天豪 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with James Lovett, CEO and Mike Cohen, Executive Chairman at Myonex. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering: How a family-owned pharmacy became a major global clinical trial supplies business... two generations later Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success James' decision to take on the baton and fuel organic and inorganic growth through client-centricity The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook Why this industry will always grow due to unmet medical needs and breakthroughs in science Michael's passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university's Katz Graduate School of Business. James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Piper speaks with Dr. Pouya Dini about UC Davis producing equine embryos by in vitro fertilization. Dr. Anna Dunaway of Purina Animal Nutrition talks about equine weight management strategies owners can use to have a meaningful impact on weight and body condition score. Dr. Gus Cothran also joins to talk about new research on the Y chromosome that will allow geneticists to trace the paternal line in horses. Brought to you by Taylor, Harris Insurance Services.Host: Piper Klemm, publisher of The Plaid HorseGuest: Dr. Pouya Dini is an associate professor at the Department of Population Health and Reproduction and the chief of the Equine Reproduction Service at the School of Veterinary Medicine at the University of California. He is a Diplomate of the European College of Animal Reproduction and the American College of Theriogenologists. Pouya holds two PhD degrees. The first PhD he obtained was a collaboration between Azad University and the University of Ghent, Belgium, and the second PhD was a collaboration between the University of Ghent and Gluck Equine Research Center at the University of Kentucky. His current research interests include the pathophysiology of the equine placenta and embryo development at the genomic level. Pouya is also the Director of the Veterinary Assisted Reproduction Laboratory, a research facility and a national embryo service provider for breeders and veterinarians located at the Department of Population Health and Reproduction at the School of Veterinary Medicine at UC Davis. Guest: Dr. Anna Dunaway is a Nutritionist on the Equine Technical Solutions team at Purina Animal Nutrition. Her Ph.D. research at the University of Nebraska focused on the use of high fat diets and manipulating the microbial community in the gut. Now at Purina, Dr. Dunaway's role includes bringing innovative solutions like the Equine MQ™ Platform from the research team out to the field.Guest: Dr. Gus Cothran was born and raised in Texas and graduated from North Texas State University where he obtained his BS and MS degrees in Biology. He then received his Ph.D. in genetics from the University of Oklahoma. Dr. Cothran worked at the University of Georgia's Savannah River Ecology Laboratory, then at the Southwest Foundation for Biomedical Research where he worked on the genetics of horses. From there, he moved to the University of Kentucky and was the Director of the Equine Parentage Testing and Research Laboratory, and Research Professor in the Department of Veterinary Science. In 2006, Dr. Cothran moved to Texas A&M University, where he was a Clinical Professor in the Department of Veterinary Integrative Biosciences. In 2016, Dr. Cothran retired but was named as an Emeritus Professor and he remains active in research activities. Dr. Cothran was a four-time Chair of the International Society of Animal Genetics standing committee for Thoroughbred DNA Typing Standardization, and a past chair of the Equine Standing Committee.Title Sponsor: Taylor, Harris Insurance ServicesSubscribe To: The Plaid Horse MagazineSponsors: Show Strides Book Series, Good Boy, Eddie and Geoff Teall on Riding Hunters, Jumpers and Equitation: Develop a Winni